HyperAcute Lung (tergenpumatucel-L) / Lumos Pharma - LARVOL DELTA

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1b/2 | N=16 | Terminated | Sponsor: NewLink Genetics Corporation | Active, not recruiting ➔ Terminated; Lack of enrollment and changing landscape of standard of care.

Combination therapy • Trial termination • Immune Modulation • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Immunotherapy study in progressive or relapsed non-small cell lung cancer (clinicaltrials.gov) - P2/3, N=240; Not yet recruiting; Sponsor: NewLink Genetics Corporation; New P2/3 trial.

New P2/3 trial • Non Small Cell Lung Cancer

Vaccine treatment for advanced non-small cell lung cancer (clinicaltrials.gov) - P1, N=54; Recruiting →Active not recruiting

Enrollment closed • Non Small Cell Lung Cancer

NewLink Genetics: Q4 & FY 2014 Results (NewLink Genetics) - Anticipated update from P2b trial (NCT01774578) in advanced lung cancer in H2 2015

Trial status • Non Small Cell Lung Cancer

NewLink Genetics presents positive phase 2 data on novel immunotherapy, tergenpumatucel-L, in non-small cell lung cancer at the ASCO 2013 annual meeting (NewLink Genetics) - P2/3, N=28; NCT01774578; Sponsor: NewLink Genetics; “All patients in the study received tergenpumatucel-L as a single agent, which resulted in long term stable disease ( > /= 16 weeks) in 8 of the 28 patients, including one patient who survived 50 months. Median overall survival of 11.3 months with tergenpumatucel-L as a single agent was also encouraging in this patient population. Sixteen of the patients whose disease progressed following tergenpumatucel-L therapy received salvage chemotherapy. The partial response rate was 31 percent (5/16) and an additional 25 percent (4/16) achieved stable disease, suggesting that tergenpumatucel-L enhanced the response rate of the salvage chemotherapy.”

P2/3 data • Non Small Cell Lung Cancer

NewLink Genetics: Annual Report 2014 (NewLink Genetics) - Anticipated expiry of patents for pharmaceutical compositions for inhibiting pre-established tumor growth comprising attenuated allogeneic tumor cells modified with alpha-Gal and methods of manufacturing in US, EU, Mexico, Japan and Canada in 2024

Anticipated patent expiry • Non Small Cell Lung Cancer

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1b/2; N=16; Active, not recruiting; Sponsor: NewLink Genetics Corporation; Recruiting ➔ Active, not recruiting; Phase classification: P1/2 ➔ P1b/2; N=115 ➔ 16

Clinical • Combination therapy • Enrollment change • Enrollment closed • Phase classification

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2b/3; N=135; Terminated; Sponsor: NewLink Genetics Corporation; Active, not recruiting ➔ Terminated; Trial primary completion date: Feb 2017 ➔ May 2016

Clinical • Trial primary completion date • Trial termination